Jaguar Health Receives Delisting Warning After Failure to Meet Continued Listing Standards

Jaguar Health, Inc. has received formal notice from its listing exchange regarding failure to satisfy continued listing standards, triggering immediate regulatory scrutiny and raising serious questions about the company's future on public markets. The SEC filing, submitted on May 4, 2026, confirms the company faces potential delisting proceedings under Item 3.01 of Form 8-K, signaling a critical juncture for the pharmaceutical firm.

The filing indicates Jaguar Health, operating under CIK 0001585608, failed to meet one or more quantitative or qualitative standards required for continued listing. Such notices typically follow sustained periods where a company falls below minimum requirements for stock price, market capitalization, shareholder equity, or operational metrics. The 142-kilobyte disclosure represents a formal regulatory record of the company's current compliance status, with the exchange now empowered to initiate delisting procedures absent corrective action or appeal.

The delisting warning places Jaguar Health under heightened pressure to either demonstrate compliance remedies or request a hearing before the exchange's adjudication panel. A delisting would force the company's shares to trade on over-the-counter markets, severely restricting investor access and liquidity. The company now faces a defined timeline to respond, present a remediation plan, or face automatic removal from its current listing venue. The situation underscores ongoing challenges within the specialty pharmaceutical sector, where capital market requirements frequently conflict with clinical development timelines and revenue constraints.